Freed AI vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI medical scribe delivering SOAP notes within 2 minutes of a visit; no EHR integration needed, making it immediately accessible to solo clinicians and small practices.
About
Freed AI is a San Francisco-based medical technology startup that provides clinicians with an AI-powered medical scribe accessible via mobile app that records patient visit audio, transcribes the conversation, and generates a complete SOAP note formatted for direct paste into any EHR. Freed differentiates from other ambient scribing tools through its simplicity and accessibility — clinicians start and stop recordings with a tap, and notes are delivered within 2 minutes without requiring EHR integrations or complex IT deployment. The product's one-tap workflow and near-immediate turnaround make it accessible to solo practitioners and small clinics that need ambient scribing without enterprise procurement processes. Freed's AI is designed to capture not just what was said but what was clinically significant, filtering conversation content to produce concise, structured notes rather than verbose transcriptions. The company has grown rapidly through physician word-of-mouth and healthcare professional communities, with thousands of clinicians using the product. Founded in 2022, Freed has gained traction as a lightweight, affordable alternative to enterprise ambient scribing platforms.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.